Tech Company Inital Public Offerings
Milestone Pharmaceuticals IPO
On 5/8/2019, Milestone Pharmaceuticals went public.
Transaction Overview
Company Name
Announced On
5/8/2019
Transaction Type
IPO
Amount
$82,500,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows: approximately $85.0 million for our Phase 3 clinical trials of etripamil in PSVT; approximately $20.0 million for pre-commercialization activities; approximately $6.0 million for our Phase 2 clinical trials of etripamil in atrial fibrillation and angina; and the remainder to fund other research and development activities, working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1111 Dr.-Frederik-Philips Blvd. 420
Saint-Laurent QC, H4M 2X6
Canada
Saint-Laurent QC, H4M 2X6
Canada
Phone
Website
Email Address
Overview
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joseph Oliveto
Chief Medical Officer
Francis Plat
Vice President
Jeffrey Nelson
Vice President
Douglas Wight
VP - Bus. Development
Lorenz Muller
VP - Manufacturing
Harish Pimplaskar
VP - Regulatory Affairs
Guy Rousseau
Browse more venture capital transactions:
Prev: 5/8/2019: MedCrypt venture capital transaction
Next: 5/8/2019: Exabeam venture capital transaction
Share this article
About Database of VC Transactions
We record funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs